Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 4
2018 6
2020 6
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
Engler T, Fasching PA, Lüftner D, Hartkopf AD, Müller V, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Wallwiener M, Beckmann MW, Hein A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Untch M, Taran FA, Enzinger HM, Krabisch P, Welslau M, Maasberg M, Hempel D, Lux MP, Michel LL, Janni W, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A. Engler T, et al. Among authors: hielscher c. Geburtshilfe Frauenheilkd. 2022 Jul 12;82(10):1055-1067. doi: 10.1055/a-1880-0087. eCollection 2022 Oct. Geburtshilfe Frauenheilkd. 2022. PMID: 36186151 Free PMC article.
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V, Hein A, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Beckmann MW, Schneeweiss A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Meyer J, Wurmthaler LA, Kurbacher CM, Wuerstlein R, Untch M, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Michel LL. Müller V, et al. Among authors: hielscher c. Eur J Cancer. 2022 Sep;172:13-21. doi: 10.1016/j.ejca.2022.05.015. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728342 Free article.
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler LA, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Hein A, et al. Among authors: hielscher c. Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23. Eur J Cancer. 2021. PMID: 34311211
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn MO, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K. Metz M, et al. Among authors: hielscher c. Support Care Cancer. 2021 Nov;29(11):6633-6643. doi: 10.1007/s00520-021-06230-9. Epub 2021 May 6. Support Care Cancer. 2021. PMID: 33956213 Free PMC article. Clinical Trial.
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Schneeweiss A, et al. Among authors: hielscher c. Breast. 2021 Feb;55:138-139. doi: 10.1016/j.breast.2020.12.007. Epub 2021 Jan 5. Breast. 2021. PMID: 33413981 Free PMC article. No abstract available.
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Lux MP, Hartkopf AD. Laakmann E, et al. Among authors: hielscher c. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):e289. doi: 10.1055/a-1306-7231. Epub 2020 Nov 25. Geburtshilfe Frauenheilkd. 2020. PMID: 33262544 Free PMC article.
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD. Laakmann E, et al. Among authors: hielscher c. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1134-1142. doi: 10.1055/a-1286-2917. Epub 2020 Nov 6. Geburtshilfe Frauenheilkd. 2020. PMID: 33173241 Free PMC article.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Michel LL, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Michel LL, et al. Among authors: hielscher c. Cancers (Basel). 2020 Oct 17;12(10):3021. doi: 10.3390/cancers12103021. Cancers (Basel). 2020. PMID: 33080911 Free PMC article.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY. Schneeweiss A, et al. Among authors: hielscher c. Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29. Breast. 2020. PMID: 32956934 Free PMC article. Clinical Trial.
20 results